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Background: Smoking is an important cause of morbidity and mortality worldwide. It is widely accepted as a major
risk factor for metabolic and cardiovascular disease. Smoking reduces insulin sensitivity or induces insulin resistance
and enhances cardiovascular risk factors such as elevated plasma triglycerides, decreases high-density lipoprotein
cholesterol and causes hyperglycemia. Several studies show that smoking is associated with metabolic
abnormalities and increases the risk of Metabolic Syndrome. The aim of this study was to estimate the prevalence
of the metabolic syndrome in a group of light and heavy smokers, wishing to give up smoking.
Methods: In this cross-sectional study all the enrolled subjects voluntary joined the smoking cessation program
held by the Respiratory Pathophysiology Unit of San Matteo Hospital, Pavia, Northern Italy.
All the subjects enrolled were former smokers from at least 10 years and had no cancer or psychiatric disorders, nor
history of diabetes or CVD or coronary artery disease and were not on any medication.
Results: The subjects smoke 32.3 ± 16.5 mean Pack Years. The prevalence of the metabolic syndrome is 52.1%:
57.3% and 44.9% for males and females respectively. Analysing the smoking habit influence on the IDF criteria for
the metabolic syndrome diagnosis we found that all the variables show an increasing trend from light to heavy
smokers, except for HDL cholesterol. A statistical significant correlation among Pack Years and waist circumference
(R = 0.48, p < 0.0001), Systolic Blood Pressure (R = 0.18, p < 0.05), fasting plasma glucose (R = 0.19, p < 0.005) and HDL
cholesterol (R = −0.26, p = 0.0005) has been observed.
Conclusions: Currently smoking subjects are at high risk of developing the metabolic syndrome.
Therapeutic lifestyle changes, including smoking cessation are a desirable Public health goal and should successfully
be implemented in clinical practice at any age.
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Smoking is an important cause of morbidity and mortal-
ity worldwide. Currently, tobacco is the second leading
cause of death in the world, accounting for about 5 mil-
lion deaths annually, equivalent to 1 out of 10 adults
worldwide [1].
It is widely accepted as a major risk factor for meta-
bolic and cardiovascular disease [2]. Previous studies
have shown that smoking reduces insulin sensitivity or
induces insulin resistance [3,4] and enhances cardiovas-
cular risk factors such as elevated plasma triglycerides,
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reproduction in any medium, provided the orand causes hyperglycemia [5-8]. Furthermore, several
studies show that smoking is associated with metabolic
abnormalities and increases the risk of Metabolic Syn-
drome (MBS) [9-11]. This syndrome is associated with
multiple metabolic alterations and hemodynamic disor-
ders. Weitzman et al. [12] have demonstrated for the first
time a dose-responsive, nicotine-confirmed relationship
between tobacco smoke and the severity of MBS, also in
adolescents, reporting that the exposure to tobacco
smoke, whether by active or passive smoking, is associated
with a 4-fold increase in the risk of MBS among adoles-
cents who are overweight or at risk for overweight.
Saarni et al. [13] investigated the association of adoles-
cent smoking with overweight and abdominal obesity in
adulthood, reporting that smoking is a risk factor ford. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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weight in women.
In Kawada’s 1-year follow-up study [14], current
smokers have a higher risk of MBS than non-smokers,
independently of age, body mass index, insulin resist-
ance, uric acid level and other lifestyle factors. In con-
trast, ex-smokers do not have a significantly greater risk
of MBS than non-smokers.
The most effective way for smokers to decrease the risk
of metabolic syndrome and cardiovascular disease is to
quit smoking [15]. However, other authors highlight that
smoking cessation is also associated with an increased risk
of MBS due to the subsequent body weight gain [4,9].
The aim of this cross sectional study is to estimate the
prevalence of the metabolic syndrome in a group of light
and heavy smokers, wishing to give up smoking.
Methods
Sampling
In this cross sectional study, the subject recruited were
all smokers attending the respiratory physio-pathological
surgical outpatient clinic of the San Matteo Hospital in
Pavia, Northern Italy, wishing to give up smoking. The
inclusion criteria were: former smokers from at least 10
years, age range from 28 to 70 years, a medical history
with no cancer or psychiatric disorders, nor history of
diabetes or CVD or coronary artery disease and were
not on any medication.
They were enrolled consecutively.
Anthropometric and functional measurements
Each subject underwent a preliminary examination with a
lung specialist and a subsequent examination to estimate
his/her nutritional status with nutritionists: a medical
doctor specialized in clinical nutrition and a registered
dietitian. The following parameters were measured:
1. Body weight, measured on subjects wearing only
underwear and without shoes, by means of a steel
yard scale (precision ± 100 g);
2. Body height, measured on subjects without shoes by
means of a stadiometer (precision ± 1 mm). BMI was
calculated as the ratio between weight (in kilograms)
and the square of height (in metres);
3. Four skinfold thicknesses (mid-triceps, mid-biceps,
subscapular and suprailiac), measured on subjects
according to standard conditions on the non-
dominant body side using a Harpenden skinfold
thickness calliper (resolution 2 mm); three
consecutive measurements were performed and the
mean of the three values was considered. The sum of
the four skinfold thicknesses was computed and the
body fat percentage was calculated according to the
predictive equations of Durnin and Womersley [16].4. Waist circumference, measured to the nearest mm
in duplicate according to standard conditions, by
placing a flexible tape midway between the lowest
rib and the iliac crest. The tape was snug, but did
not squeeze or compress the skin, and was parallel
to the floor. The measure was collected on
unclothed, relaxed subjects, after exhaling.
5. Systolic (SBP) and diastolic (DBP) blood pressure,
measured according to standard conditions using a
sphygmomanometer; three measurements were
performed at intervals of 2–5 minutes and then
mean of the three values was considered.
6. Heart rate measured according to standard
conditions expressed as beats per minute (bpm),
finding the pulse at the ventral aspect of the wrist
on the side of the thumb (radial artery).
7. Routine haematochemical levels and any drug
therapy prescribed for cigarette withdrawal by the
lung specialist were recorded at every medical
examination. The patient’s life style was investigated
by an interview conducted by a trained dietitian, in
order to evaluate the kind, frequency and intensity
of physical activity.
Smoking habits
Three smokers category have been considered: light
smokers consuming till 19 Pack per Years (PY), moder-
ate smokers ≥ 20–39 PY and heavy smokers ≥ 40 PY [17].
PY means cigarettes smoked per day times years of
smoking, divided by 20 [18].
Diagnostic criteria for metabolic syndrome
Several definitions exist for MBS [19].
In our study we used the International Diabetes Feder-
ation (IDF) clinical criteria [20], providing an universally
accepted diagnostic tool that is very easy to use in clin-
ical practice.
The IDF consensus definition includes:
▪ Ethnic specific values for waist circumference:
Central obesity is defined as waist circumference
≥94 cm for Euripides men and ≥80 cm for Euripides
women, with ethnicity specific values for other
groups; nevertheless if BMI is >30 kg/m2, central
obesity can be assumed and waist circumference
does not need to be measured.
▪ plus any two of the following four factors:
* raised Triglycerides (TG) level: ≥ 150 mg/dL
(1.7 mmol/L), or undergoing specific treatment
for this lipid abnormality;
* reduced HDL cholesterol: < 40 mg/dL (1.03
mmol/L) in males and < 50 mg/dL (1.29 mmol/L)
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DBP ≥ 85 mm Hg, or undergoing a specific anti-
hypertensive treatment;
* raised fasting plasma glucose (FPG) ≥ 100 mg/dL
(5.6 mmol/L), or previously diagnosed type 2
diabetes (if glucose concentration is above 5.6
mmol/L or 100 mg/dL, OGTT is strongly
recommended but is not necessary to define
presence of the syndrome).Informed consent and ethical approval
Written informed consent was obtained from all partici-
pants prior to their inclusion in the study, which was
performed in accordance with the ethical standards laid
down in the appropriate version of the 1994 Declaration
of Helsinki and approved by the University of Pavia’s
Faculty of Medicine Ethical Committee.
Statistical analysis
Comparison between males and females variables was
analysed with paired Student’s t-test.
Pearson’s correlation coefficient was used in order to
determine the association among all the variables inves-
tigated, in particular with the smoking habits (Packs per
Year - PY).
Analysis of variance was used to compare light, mod-
erate and heavy smokers.
Data were analyzed using the SPSS for PC statistical
software package version 18 (SPSS Inc., Chicago, IL,
USA). All the results are reported as mean ± standard
deviation. The statistical significance level was set to
p < 0.05 for all tests.
Results
Of the 160 subjects assessed for eligibility, 117 (73.1% of
the whole sample) were included in the study (68 malese 1 Baseline characteristics of the sample
bles Men
n = 68
ears) 49.7 ± 11.2
g/m2) 26.6 ± 4.9
ass (%) 25.6 ± 6.1
circumference (cm) 97.7 ± 14.3
erides (mg/dL) 188 ± 125
holesterol (mg/dL) 43 ± 14
glycaemia (mg/dL) 100 ± 27
mmHg) 129 ± 14
(mmHg) 83 ± 8
ears (n) 35.2 ± 8.8
ystolic Blood Pressure.
iastolic Blood Pressure.and 49 females). Forty-three individuals were excluded
either because under the minimum age-range (n = 8) or
affected by metabolic, cardiovascular, psychiatric and/or
oncological pathologies (n = 35). The mean age of the
sample was 50.1 ± 11.3 years. The mean BMI of the whole
sample was 25.6 ± 4.8 kg/m2. Table 1 shows the age and
the anthropometric characteristics of the sample.
Waist circumference, body fat mass, BMI and PY are
statistically different between gender.
Body fat percentage has been estimated by skinfolds
thickness. We found that women have a higher fat mass
percentage than men who show greater circumference
waist and higher BMI.
A central fat distribution was found in the 73.7% of
the sample; in the 71% of the same subjects the waist
circumference is above the 94 and 80 cm cut off levels
respectively for men and women for the European popu-
lation according to IDF [21].
Biochemical and functional measurements, suggested
by IDF, as MBS diagnostic criteria, are reported in
Table 1.
Statistical significant differences between men and
women for triglycerides and HDL cholesterol emerged.
Waist circumference is positively correlated both to
basal glycaemia (R = 0.41, p <0.0001), TG concentration
(R = 0.26, p <0.00 5), SBP (R = 0.30, p < 0.001) and DBP
(R = 0.27, p < 0.005).
The subjects smoke 32.3 ± 16.5 mean PY. In Table 2
are reported the characteristics of the sample subdivided
in light, moderate and heavy smokers.
Women resulted mainly light smokers (n = 13) and
moderate smokers (n = 30) compared to men.
All the variables show an increasing trend from light
to heavy smokers, except for HDL cholesterol, which de-
creases as expected. The same trend has been observed
adjusting for age, gender and BMI.Women Total p-value
n = 49 n = 117
50.7 ± 11.7 50.1 ± 11.3 p = 0.639
24.3 ± 4.3 25.6 ± 4.8 p < 0.01
35.5 ± 6.7 29.7 ± 7.9 p < 0.0001
86.5 ± 13.7 93.0 ± 15.0 p < 0.0001
140 ± 56 168 ± 105 p < 0.01
51 ± 12 46 ± 14 p < 0.002
93 ± 18 97 ± 24 p = 0.157
126 ± 10 128 ± 13 p = 0.250
81 ± 6 83 ± 7 p = 0.148
27.4 ± 9.6 32.3 ± 16.5 p < 0.001
Table 2 Characteristics of the whole sample subdivided in light, moderate and heavy smokers.
Variable Light smokers Moderate smokers Heavy smokers
(n = 17) (n = 41) (n = 59)
Age (years) 39.2 ± 12.7* 46.2 ± 9.6 56.6 ± 7.8
BMI (kg/m2) 22.3 ± 3.5* 25.6 ± 4. 3 26.6 ± 5.1
Fat mass (%) 35.5 ± 10.0 40.5 ± 11.9 41.1 ± 12.5
Waist circumference (cm) 82.7 ± 12.7* 92.5 ± 13.3 96.5 ± 13.6
TG (mg/dL) 124 ± 49* 164 ± 72* 190 ± 44
HDL Col (mg/dL) 52 ± 13 46 ± 13 45 ± 15
Basal glycaemia (mg/dL) 84 ± 14 94 ± 16 104 ± 29
SBP (mmHg) 124 ± 11 126 ± 13 132 ± 13
DBP (mmHg) 82 ± 6 83 ± 8 84 ± 7
Years smoked (years) 16.6 ± 7.8* 29.1 ± 9.7* 40.9 ± 8.6
PY3 (n) 12.5 ± 6.2* 32.1 ± 9.9* 63.4 ± 15.0
* p < 0.05.
1 SBP Systolic Blood Pressure.
2 DBP Diastolic Blood Pressure.
3 PY Pack Years.
Table 3 Criteria values for Metabolic Syndrome (MBS)
diagnosis, age, BMI, body fat mass, PY in the two sub
samples with and without MBS (MBS vs NMBS)
Variable MBS (n 61) NMBS (n 56) p-value
Age (years) 53.5 ± 10.2 46.5 ± 11.5 p = 0.0006
Males (n) 35 33
BMI (kg/m2) 27.9 ± 4.4 23.1 ± 3.8 p < 0.0001
Fat mass (%) 42.3 ± 14.6 37.8 ± 8.5 p = 0.04
Waist circumference (cm) 101.0 ± 12.8 84.3 ± 12.3 p < 0.0001
Triglycerides (mg/dL) 201 ± 12.1 131 ± 66 p = 0.0002
HDL Cholesterol (mg/dL) 53 ± 15 41 ± 10 p < 0.0001
Basal glycaemia (mg/dL) 107 ± 28 86 ± 10 p < 0.0001
SBP1 (mmHg) 135 ± 13 121 ± 8 p < 0.0001
DBP2 (mmHg) 86 ± 7 79 ± 5 p < 0.0001
PY3 (n) 51.0 ± 28.0 36.8 ± 23.5 p < 0.05
1 SBP Systolic Blood Pressure.
2 DBP Diastolic Blood Pressure.
3 PY Pack Years.
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relation among PY and body weight (R = 0.40, p < 0.0001),
BMI (R = 0.43, p < 0.0001), waist circumference (R = 0.48,
p < 0.0001), fat mass (R = 0.45, p < 0.01), SBP (R = 0.18,
p < 0.05), fasting plasma glucose (R = 0.19, p < 0.005).
On the other hand, an inverse correlation between PY
and HDL cholesterol (R = −0.26, p = 0.0005) has been
observed. HDL cholesterol is also inversely correlated
to body weight (R = − 0.23,p < 0.01), BMI (R = − 0.22,
p < 0.05), waist circumference (R = − 0.31, p < 0.0005), SBP
(R = − 0.19,p < 0.05), fasting plasma glucose (R = − 0.12,
p < 0.001) and TG (R = − 0.46, p <0.0001).
In the whole sample the MBS prevalence is 52.1%:
57.3% and 44.9% for males and females respectively.
Analysing the prevalence of the single IDF criteria for
the MBS diagnosis we found that a high waist circumfer-
ence value is the most frequently relieved parameter (in
88.2% of females and 91.5% of males), followed by raised
TG in both genders (81.1% in females and 92.3% in males)
and SBP in males (86.6%), and finally by lowered HDL
levels in females (75.6%) and high DBP in males (82.4%).
Table 3 shows all the variables considered in the sub-
jects with or without MBS. All the parameters are
significantly higher (p ranges from <0.05 to < 0.0001) in
patients affected by MBS, except for HDL cholesterol
value, which is lower.
The sample’s life style can be described overall as sed-
entary, since only 42.2% of the subjects regularly walk
for not more than half an hour per day and 37% of the
whole sample regularly walk for not more than half an
hour per week, without significant differences between
gender; 80% of the sample does not practice any sports
nor any programmed physical activity (78.8% of males
and 81.6% of females).Discussion
Tobacco smoking is a major risk factor for several dis-
eases, including MBS and consequently cardiovascular
disease (CDV).
Using racial- or ethnic-specific International Diabetes
Federation criteria for waist circumference, the MBS
age-adjusted prevalence in the USA is 38.5% and it is
higher in former smokers [22].
Currently smoking men and women are at significantly
higher risk of developing MBS, increasing directly the
risk of atherosclerotic cardiovascular disease develop-
ment [23].
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obesity, MBS risk as well as association with obesity and
smoking.
The association between smoking and MBS remains
even after adjusting for other covariates, possibly a re-
flection of the effect of cigarette smoking on insulin
resistance.
In according with Wada et al. [4] we found a positive
dose–response relationship between the daily number of
cigarettes and MBS prevalence rate.
This relationship is dependent on the number of ciga-
rettes smoked daily: BMI, waist circumference, total
cholesterol, TG and glucose concentration are positively
associated with smoking intensity.
Cigarette smoking is an independent predictor of de-
veloping metabolic abnormalities in middle age over-
weight and obese adults, lowering cigarette smoking
reduces risk of metabolic abnormalities, particularly in
men [24]. Cigarette smoking as well as physical inactivity
and obesity are associated with higher risk of the meta-
bolic syndrome in elderly men too [25]; stopping smok-
ing is one of the lifestyle changes, even at older ages,
associated with a significant lowering risk of developing
MBS [25].
In our study the prevalence of MBS in the females, al-
though mainly light and moderate smokers compared to
men, and despite significantly lower mean BMI (overall
normo-weight females vs overweight males), may be
partly explained by gender-difference, higher total body
fat mass and fat distribution (higher waist circumfer-
ences compared to the gender specific IDF cut-points
for Euripids). The women in our sample were mainly
perimenopausal and it is possible that hormonal factors,
in part, exert their influence on body fat distribution, as
well as the age related increase of physical inactivity or
higher rates of sedentary [24,26,27]. The sex difference is
explained by others as a stronger anti-estrogenic effect of
nicotine in women than in men [28]. Cigarette smoking,
particularly smoking ≥20 cigarettes/day, has been associ-
ated with larger waist circumference and higher waist:hip
ratio (WHR) in pre- and post-menopausal women after
adjusting for potential confounding factors [29].
Claire C et al. [30] found that among middle-aged
smokers of both sexes, waist circumference increased
with number of cigarettes smoked, the authors conclude
that among smokers, cigarettes smoked per day were
positively associated with central fat accumulation, par-
ticularly in women [30].
Waist circumference as well as WHR is an indicator of
the amount of visceral adipose tissue [31]. In our study
smokers tend to have a large waist circumference that
increased proportionally with the number of the pack
years (R = 0.48, p < 0.0001) in agreement with Shimokata
et al. [32].Smoking seems to accelerate visceral fat accumulation
and promote obesity-related disorders. Medical research
has focused on visceral adiposity as a target for the man-
agement of the MBS [33]. Distribution of body fat is
more important than the amount of fat as a prognostic
factor for life expectancy [34].
Nicotine, carbon monoxide, and other metabolites
from smoking also play important roles in insulin resist-
ance [31]. Indeed, several studies in the past have shown
that nicotine leads to insulin resistance, has an anti-
estrogenic effect and increases the level of stress hor-
mones like cortisol [35-37].
Cigarettes smoking is a strong independent risk factor
for cardiovascular disease as well as for non insulin
dependent diabetes mellitus [8,38].
MBS and glucose intolerance are regarded as distur-
bances with a common background and strong inter-
relations such as hyperglycemia, decreases high-density
lipoprotein cholesterol (HDL-C) and elevated plasma tri-
glycerides [39].
In according with other authors [11,40] we found that
smokers had features of insulin resistance syndrome in-
cluding low HDL Cholesterol, high serum triacylglicerol,
high fasting glucose. In our study all these parameters
are positively associated with smoking intensity: there is
a statistical significant correlation among Packs Year
(PY) and BMI, waist circumference, fasting plasma glu-
cose and there is an inverse correlation between packs
smoked per year and HDL cholesterol.
Low serum concentrations of high-density lipoprotein-
cholesterol (HDL-C), defined as <1 mmol/L (40 mg/dL)
in both sexes, or <1 mmol/L in men and <1.3 mmol/L
(50 mg/dL) in women, are independent risk factors for
coronary heart disease (CHD). The causes of low HDL-
C include rare genetic disorders such as Tangier and
secondary factors such as smoking, type 2 diabetes,
metabolic syndrome and abdominal obesity [41,42].
The current International guidelines for the manage-
ment of dyslipidemia recommend a change in lifestyle
for people with low HDL-C, focussing on weight reduc-
tion, increased physical activity and smoking cessation
[43,44], with evident benefits on the overall CVD risk
and specifically on HDL-C [43].
The visceral fat accumulation and insulin resistance
may represent an important link between cigarette
smoking and the risk of cardiovascular disease [31]. Fur-
ther research is needed in this area, but these findings
indicate that more emphasis should be placed on the
risk of central obesity among smokers and those who
are quitting smoking. Almost any smoker is aware of the
association between quitting smoking and the risk of
subsequent body weight gain due to increased energy
intake, decreased metabolic rate, increased physical in-
activity [45] but, on the other hand not all of them know
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and vegetable intake, excessive alcohol consumption, sed-
entary lead to weight gain and might partly explain why
smokers tend to accumulate fat specifically in the abdom-
inal area [31,46]. Besides a recent research reported that
smoking cessation may be associated not only with in-
creased body weight, fat mass, but also with increased lean
and functional mass suggesting a novel and important
finding on the benefits of quitting smoking [47].
Limitations of current study
Our results must be interpreted in light of the study limi-
tations. First, the study is a cross-sectional one, our results
do not investigate the MBS prevalence data before and
after quitting smoking. Second, inflammatory and pro-
coagulant variable such as C-reactive protein, fibrinogen
as well as citokynes concentrations were not measured.
On the other hand one of the study's strength is the
use of anthropometric measurements instead of self-
reported weight and height, as well as waist circumfer-
ence assessment. People tend to over report their height
and under report their weight, resulting in an underesti-
mation of BMI. Under reporting of weight is more
prevalent in those who are overweight or obese than in
normal-weight persons [48].
Conclusions
Currently smoking subjects are at high risk of develop-
ing the metabolic syndrome. Intervention studies offer-
ing support to smokers willing to quit through physical
activity promotion and healthy diet in order to reduce
smoking prevalence whereas avoid weight gain following
cessation is a desirable public health goal.
Medical management and prevention programs should
take into account that concerns about post cessation weight
gain may deter numerous persons from quitting smoking
[48], such persons should be made aware that smoking is
not an efficient way to control body weight, does not help
prevent obesity and could favourite visceral fat accumula-
tion and increase the risk of metabolic syndrome.
According to our data, we suggest to specifically tar-
get, heavy smokers, because of their increased MBS risk
and find support to assist them in smoking cessation.
This deserves priority [49, 50] and should successfully
be implemented in clinical practice at any age.
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